Patients with milder psoriatic arthritis (PsA) at baseline were more likely to respond to biologic disease-modifying antirheumatic drugs by their second follow-up visit compared with non-responders, according to recent research.
Philip J. Mease, MD, from the Swedish Medical Center and University of Washington, Seattle, WA, and colleagues found that patients in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) registry who displayed at baseline with milder PsA had better outcome scores compared with non-responders.
The data were presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (AHRP) Annual Meeting in Washington, D.C.
Of the 148 patients in the study who met inclusion criteria, 34 patients (23.0%) were responders and 114 patients (77.0%) were non-responders, according to the abstract. Patients were included in the study if they had a diagnoses of PsA, were at least 18 years of age, were enrolled in the registry between March 2013 and March 2016. All patients were currently using biologics at baseline, with 142 patients (96.6%) receiving anti-tumor necrosis factor agents.
Patients who responded to biologics reported a lower Health Assessment Questionnaire score (0.6 vs 1.0; P = .001), mean visual analog pain scale (VAS) score (35.7 vs 51.2; P = .05), VAS fatigue score (42.4 vs 54.1; P = 0.002), mean tender joint count (3.4 vs 7.4; P = .02) as well as Bath Ankylosing Spondylitis Disease Activity Index score (3.4 vs 5.0; P = .001) and Functional Index score (2.0 vs 4.0; P < .001).
The researchers noted patients in both groups were matched by age, race, gender, duration of disease, and both prior and current treatments. Comorbidities such as cancer, cardiovascular disease, infection, and diabetes were similar in each cohort, and both groups also had similar multiple disease measures such as acute phase reactants, Clinical Disease Activity Index, enthesitis, and dactylitis counts.
Summary and Clinical Applicability
“This study from the Corrona PsA/SpA registry found that only 23.0% of patients achieved MDA with their index biologic at the time of the second follow-up visit (mean [SD] follow-up, 15.7 [3.7] months) and were considered responders,” Dr Mease and colleagues concluded.
“Both cohorts were similar with regards to several baseline demographic and clinical characteristics; however, responders generally had less severe disease at enrollment compared with non-responders.”
Dr Mease is a paid consultant for Celgene, Novartis, AbbVie, Amgen, BMS, Lilly, Pfizer and UCB; is a paid consultant for Celgene, Corrona, Novartis, AbbVie, Amgen, BMS, Crescendo, Genentech, Janssen, Lilly, Merck, Pfizer and UCB; and is on the speaker’s bureau for AbbVie, Amgen, BMS, Crescendo, Celgene, Genentech, Janssen, Pfizer and UCB. Drs Karki, Liu, and Pandurengan are employees of Corrona, LLC. Dr Kavanaugh is a paid consultant for Amgen, AbbVie, Janssen, Pfizer and Novartis. Dr Ritchlin is a paid consultant for Amgen, Janssen Pharmaceutica Product, L.P., and UCB. Dr Huynh is on the speaker’s bureau for AbbVie and BMS. Dr Palmer is an employee of Novartis Pharmaceuticals Corporation. Dr Greenberg holds stock or stock options and is an employee of Corrona, LLC, and is a paid consultant of Eli Lilly, Genentech, Janssen, Novartis and Pfizer.
Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh DH, Pandurengan R, Palmer JB, Greenberg JD. Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry [abstract]. Arthritis Rheumatol.2016; 68 (suppl 10). http://acrabstracts.org/abstract/baseline-patient-characteristics-associated-with-response-to-biologic-therapy-in-patients-with-psoriatic-arthritis-enrolled-in-the-corrona-psoriatic-arthritisspondyloarthritis-psaspa-registry/. Accessed November 18, 2016.